Ratings United Therapeutics Corporation

Equities

UTHR

US91307C1027

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
255.1 ^USD	+8.88%		+7.65%	+16.03%

May. 01	Transcript : United Therapeutics Corporation, Q1 2024 Earnings Call, May 01, 2024
May. 01	United Therapeutics Q1 Net Income, Revenue Advance; Shares Rise Pre-Bell	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The company's attractive earnings multiples are brought to light by a P/E ratio at 10.89 for the current year.
The company has a low valuation given the cash flows generated by its activity.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
UNITED THERAPEUTICS CORPORATION	+16.03%	11.32B	B+
IQVIA HOLDINGS INC.	+0.67%	42.4B	B
LONZA GROUP AG	+46.79%	40.04B	A
CELLTRION, INC.	-6.20%	28.31B	C
ICON PUBLIC LIMITED COMPANY	+6.55%	24.94B	B-
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.96B	B
MEDPACE HOLDINGS, INC.	+29.96%	12.3B	C+
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.95B	C+
BIO-TECHNE CORPORATION	-4.80%	11.55B	B+
QIAGEN N.V.	-4.38%	9.5B	A

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes